Let’s Super Charge Care Management

 

Supercharging care management, a central concern in healthcare requires understanding the powerful technological tools available to make a difference. Artificial Intelligence (AI) stands poised to redefine patient care coordination. The discussion around such technological leaps is not just timely but crucial, considering the ever-rising healthcare costs and the need for improved patient outcomes. This context sets the stage for a pertinent conversation about how companies like Laguna Health deploy advanced AI tools, like Natural Language Processing (NLP), to revolutionize the industry.

The latest Healthcare Rethink episode, a podcast series by FinThrive, features an in-depth discussion with Yoni Shtein, CEO and Co-Founder of Laguna Health, led by host Brian Urban. The dialogue focuses on how Laguna Health is implementing AI to enhance the efficiency of care management and adherence to care plans.

Highlights from the episode include:

  • The integration of NLP and AI to relieve the administrative burden on care managers
  • Laguna Health’s contribution to diminishing hospital readmissions and reducing healthcare costs
  • The incorporation of social determinants into care plans, aiming to elevate patient care standards

Yoni Shtein’s path to healthcare was deeply personal, ignited by a family loss. With a professional foundation as a software engineer at Microsoft and a track record in business model innovation, Shtein and his business partner, Yael Adam, contribute deep insights from her tenure at a digital health startup, making the Laguna Health leadership team uniquely equipped to drive progress in the tech-healthcare sector and supercharge care management.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…